MedPath

Caesarean and Corticotherapy

Phase 4
Completed
Conditions
Neonatal Distress
Interventions
Other: placebo
Drug: betamethasone
Registration Number
NCT00446953
Lead Sponsor
University Hospital, Strasbourg, France
Brief Summary

Comparison of two randomized group :

* caesarean section planned at 38 weeks after 2 antenatal injections of 12 mg of betamethasone 48 h before.

* caesarean section planned at 39 weeks without corticosteroid.

The aim is to demonstrate that programming caesarean section at 38 weeks of pregnancy, after antenatal corticosteroid, allows to avoid caesarean section in emergency (because of a labour before 39 weeks), without increasing the neonatal respiratory distress rate.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
200
Inclusion Criteria
  • woman who needs elective caesarean section
Read More
Exclusion Criteria
  • multiple pregnancy
  • toxaemia
  • rhesus immunization
  • fetal infection
  • maternal gastro-duodenal ulcer
  • mother HIV+
  • prior injection of corticosteroid during the pregnancy
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
2placebono drugs
1betamethasone2x 12 mg betamethazone
Primary Outcome Measures
NameTimeMethod
Neonatal respiratory distress15 days
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (5)

Cmco-Sihcus

🇫🇷

Schiltigheim, France

Le Parc Centre pour la Mère et l'Enfant

🇫🇷

Colmar, France

Centre Hospitalier de Haguenau

🇫🇷

Haguenau, France

Hôpital de Hasenrain

🇫🇷

Mulhouse, France

Hôpital de Hautepierre

🇫🇷

Strasbourg, France

© Copyright 2025. All Rights Reserved by MedPath